Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer

<div>Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer</div>

Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer

Written by Customer Service on March 14, 2022. Posted in Public Companies.

New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomas nextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) — Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer. nextHERIZON is an open-label, multi-center,...

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023 Lecanemab collaboration to continue unchanged globally Lecanemab supply agreement to extend to 10 years from 5 years for commercial manufacturing by Biogen Both companies will continue to collaborate together with the goal of bringing more options to patients and maximizing the value of both products CAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of...

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

Written by Customer Service on March 14, 2022. Posted in Public Companies.

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts First clinical data demonstrating effectiveness of HGNS to treat CCC patients As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months, and reports 60%+ responder rates for all three cohorts Exceeds 70% mean reduction in AHI4 among responders in both CCC and non-CCC cohorts Mont-Saint-Guibert, Belgium – March 14, 2022, 11:30pm CET / 6:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided additional data from its BETTER SLEEP clinical trial that it showcased in a poster presentation at the 16th World...

Cardinal Energy Ltd. Announces Fourth Quarter 2021 and Year-End Financial Results

Written by Customer Service on March 14, 2022. Posted in Public Companies.

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Cardinal Energy Ltd. (“Cardinal” or the “Company“) (TSX: CJ) is pleased to announce its operating and financial results for the fourth quarter and year ended December 31, 2021. FINANCIAL HIGHLIGHTS FROM THE FOURTH QUARTER OF 2021 Fourth quarter 2021 production increased 10% over the same period in 2020; In the fourth quarter of 2021, adjusted funds flow(1) increased 293% to $53.5 million ($0.36 per basic share) as compared to the fourth quarter of 2020. Adjusted funds flow(1) for 2021 increased to $132.5 million, a 202% increase over 2020; West Texas Intermediate (“WTI”) oil prices averaged approximately US$77/bbl resulting in free cash flow(1) of $35.4 million in the fourth quarter of 2021 contributing to a fourth quarter net debt(1) reduction...

Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

Written by Customer Service on March 14, 2022. Posted in Public Companies.

MONTREAL, March 14, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on March 10, 2022 with certain institutional and accredited investors. In connection with the private placement, the Company issued (i) 2,301,353 shares of its Common Stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of Common Stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Investor Warrants to purchase up to 1,302,251...

Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering

Written by Customer Service on March 14, 2022. Posted in Public Companies.

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B convertible preferred stock and Series A warrants to purchase up to an aggregate of 24,250,000 shares of common stock and Series B warrants to purchase up to an aggregate of 24,250,000 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.20 per share. The shares of preferred stock issued in the offering are convertible into...

Petrus Announces Closing of Strategic Acquisition of Cardium Assets in Ferrier

Written by Customer Service on March 14, 2022. Posted in Public Companies.

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company“) (TSX: PRQ) is pleased to announce that it has closed its previously announced acquisition of a privately owned limited partnership and its general partner for total consideration of approximately $14.4 million, consisting of the issuance of 10 million common shares of the Company. Petrus’ approved 2022 capital budget remains at $50-$55 million following the acquisition. Capital will be largely focused on the drilling, completion and tie-in of 14 net wells in Ferrier. The 2022 budget was constructed using a price forecast of WTI at US$69.00/bbl, AECO at $3.20/GJ and a foreign exchange rate of US$0.79. Through the successful execution of this capital plan and with the acquired entities now included, Petrus...

Firm Capital Apartment REIT Reports Q4/2021 Results and 4% NAV Increase to USD $10.15 (CAD $12.86) Per Unit

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

All figures in $USD unless otherwise noted TORONTO, March 14, 2022 (GLOBE NEWSWIRE) — Firm Capital Apartment Real Estate Investment Trust (“the “Trust”), (TSXV: FCA.U), (TSXV: FCA.UN) is pleased to report its financial results for the three months ended December 31, 2021: EARNINGS For the three months ended December 31, 2021, net income was approximately $3.5 million, in comparison to the $2.5 million reported for the three months ended December 31, 2020. For the year ended December 31, 2021, net income was $3.8 million, in comparison to the $5.6 million net income reported for the year ended December 31, 2020; Excluding non-cash fair value adjustments, net income was $0.5 million for the three months ended December 31, 2021, in line with the $0.5 million reported for the three months ended December 31, 2020. Excluding non-cash...

Westport Fuel Systems Reports Fourth Quarter and Full-Year 2021 Financial Results

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“WFS”) (TSX:WPRT / Nasdaq:WPRT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on operations. All figures are in U.S. dollars unless otherwise stated. FOURTH QUARTER 2021 HIGHLIGHTS Revenue of $82.7 million, a decrease of 1% over the same period last year, reflecting manufacturing delays caused by the shortage of semiconductors in our heavy and light-duty businesses Net income of $5.3 million or $0.03 per share; Adjusted EBITDA1 was $10.0 million, or a $1.9 million improvement year-over-year Completed refinancing of $20 million Term Loan from Export Development Canada FULL-YEAR 2021 HIGHLIGHTS Revenue of $312.4 million, up 24% vs. 2020 due to the continued recovery of sales...

Logan Ridge Finance Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

During 2021 Logan Ridge further de-levered and strengthen its portfolio, redeployed equity investments into interest earnings investments and lowered overall cost of debt; well positioned to generate higher returns on investments in 2022 NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) — Logan Ridge Finance Corporation (“Logan Ridge”, “LRFC” or the “Company”) (Nasdaq: LRFC) announced today its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights During the year ended December 31, 2021, we have successfully de-levered the Company from 1.98x as of December 31, 2020 to 1.17x as of December 31, 2021. As of September 30, 2021 our debt-to-equity ratio was 1.13x. As of December 31, 2021, 34% of the Company’s investment portfolio at fair value was invested in assets originated...

Day: March 14, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice